About Vision Sciences (NASDAQ:CGNT)
Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes. In addition, the company offers Urgent PC System, a neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder; and Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. Further, it provides Macroplastique products for the treatment of vesicoureteral reflux; PTQ Implants to treat fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants to enhance speech and swallowing function in patients with unilateral vocal cord paralysis. Additionally, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical, Inc. sells its products through a direct sales force and a network of distributor organizations. The company was founded in 1987 and is headquartered in Minnetonka, Minnesota.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGNT
CUSIPN/A
Phone952-426-6140
Debt
Debt-to-Equity RatioN/A
Current Ratio4.66%
Quick Ratio3.90%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$56.32 million
Price / Sales4.16
Cash Flow$0.0392 per share
Price / Cash98.23
Book Value$1.05 per share
Price / Book3.67
Profitability
EPS (Most Recent Fiscal Year)($0.01)
Net Income$-880,000.00
Net Margins-1.57%
Return on Equity-1.39%
Return on Assets-1.21%
Miscellaneous
Employees208
Outstanding Shares60,910,000
Vision Sciences (NASDAQ:CGNT) Frequently Asked Questions
What is Vision Sciences' stock symbol?
Vision Sciences trades on the NASDAQ under the ticker symbol "CGNT."
How were Vision Sciences' earnings last quarter?
Vision Sciences Inc. (NASDAQ:CGNT) issued its quarterly earnings data on Tuesday, November, 3rd. The medical device company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The medical device company earned $11.80 million during the quarter, compared to the consensus estimate of $11.45 million. Vision Sciences had a negative net margin of 1.57% and a negative return on equity of 1.39%. View Vision Sciences' Earnings History.
When is Vision Sciences' next earnings date?
What price target have analysts set for CGNT?
3 brokers have issued 1-year price objectives for Vision Sciences' stock. Their forecasts range from $4.00 to $5.00. On average, they expect Vision Sciences' share price to reach $4.5833 in the next year. View Analyst Ratings for Vision Sciences.
Who are some of Vision Sciences' key competitors?
Some companies that are related to Vision Sciences include Rockwell Medical (RMTI), Helius Medical Technologies (HSDT), Zynex (ZYXI), Biolife Solutions (BLFS), Second Sight Medical (EYES), Viveve Medical (VIVE), Edap Tms (EDAP), IRIDEX (IRIX), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), Digirad (DRAD), Dynatronics (DYNT), Aradigm (ARDM), EnteroMedics (RSLS), CHF Solutions (CHFS), FC Global Realty (FCRE), Trimedyne (TMED) and IMRIS (IMRSQ).
Who are Vision Sciences' key executives?
Vision Sciences' management team includes the folowing people:
- Mr. Darin Hammers, Chief Exec. Officer, Pres & Director (Age 53)
- Mr. Brett A. Reynolds, CFO, Sr. VP & Corp. Sec. (Age 49)
- Mr. Chris Arnold, VP of Global Sales (Age 50)
- Mr. Larry Heinemann, VP of Corp. Devel. (Age 66)
- Mr. Ash Keswani, Sr. VP of Marketing & Bus. Devel.
Has Vision Sciences been receiving favorable news coverage?
News coverage about CGNT stock has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vision Sciences earned a news impact score of 0.20 on Accern's scale. They also assigned media headlines about the medical device company an impact score of 45.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Vision Sciences' major shareholders?
Vision Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include
CAMDEN MERGER SUB, INC.
(59.40%). Company insiders that own Vision Sciences stock include Kenneth A Samet and Lewis C Pell. View Institutional Ownership Trends for Vision Sciences.
How do I buy shares of Vision Sciences?
Shares of CGNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vision Sciences' stock price today?
One share of CGNT stock can currently be purchased for approximately $3.85.
How big of a company is Vision Sciences?
Vision Sciences has a market capitalization of $234.49 million and generates $56.32 million in revenue each year. The medical device company earns $-880,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Vision Sciences employs 208 workers across the globe.
How can I contact Vision Sciences?
Vision Sciences' mailing address is 5420 FELTL ROAD, MINNETONKA MN, 55343. The medical device company can be reached via phone at 952-426-6140 or via email at [email protected]
MarketBeat Community Rating for Vision Sciences (CGNT)
MarketBeat's community ratings are surveys of what our community members think about Vision Sciences and other stocks. Vote "Outperform" if you believe CGNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vision Sciences (NASDAQ:CGNT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Vision Sciences in the last 12 months. Their average twelve-month price target is $4.5833, suggesting that the stock has a possible upside of 19.05%. The high price target for CGNT is $5.00 and the low price target for CGNT is $4.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.33 | 2.33 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.5833 | $4.5833 | $4.5833 | $5.00 |
| Price Target Upside: | 19.05% upside | 19.67% upside | 60.26% upside | 73.61% upside |
Vision Sciences (NASDAQ:CGNT) Consensus Price Target History
Vision Sciences (NASDAQ:CGNT) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/23/2018 | Roth Capital | Downgrade | Buy -> Hold | $4.00 | Low |  |
| 3/13/2018 | Aegis | Downgrade | Buy -> Hold | $4.75 | Low | |
| 10/6/2017 | JMP Securities | Initiated Coverage | Mkt Outperform -> Outperform | $5.00 | N/A | |
(Data available from 4/22/2016 forward)
Vision Sciences (NASDAQ:CGNT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Vision Sciences (NASDAQ CGNT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 62.70%
Institutional Ownership Percentage: 14.52%
Vision Sciences (NASDAQ CGNT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/18/2016 | Kenneth A Samet | Director | Buy | 25,000 | $2.47 | $61,750.00 | 125,000 | |
| 6/10/2016 | Lewis C Pell | Director | Buy | 13,291 | $0.95 | $12,626.45 | 2,363,300 | |
| 6/1/2016 | Lewis C Pell | Director | Buy | 894 | $0.75 | $670.50 | 2,350,009 | |
| 5/31/2016 | Lewis C Pell | Director | Buy | 500,000 | $0.79 | $395,000.00 | 1,999,115 | |
| 5/21/2015 | Kevin H Roche | Director | Buy | 10,000 | $1.68 | $16,800.00 | | |
| 5/19/2015 | Kevin H Roche | Director | Buy | 10,000 | $1.60 | $16,000.00 | | |
| 2/20/2015 | Lewis C Pell | Director | Buy | 20,000 | $0.51 | $10,200.00 | | |
| 2/19/2015 | Lewis C Pell | Director | Buy | 10,000 | $0.48 | $4,800.00 | | |
| 2/18/2015 | Lewis C Pell | Director | Buy | 30,000 | $0.45 | $13,500.00 | | |
| 2/13/2015 | Lewis C Pell | Director | Buy | 20,000 | $0.47 | $9,400.00 | | |
| 2/11/2015 | Lewis C Pell | Director | Buy | 35,000 | $0.46 | $16,100.00 | | |
| 12/23/2014 | Lewis C Pell | Director | Buy | 80,000 | $0.85 | $68,000.00 | | |
| 12/22/2014 | Lewis C Pell | Director | Buy | 40,000 | $0.86 | $34,400.00 | | |
| 9/23/2014 | Lewis C Pell | Director | Buy | 5,000 | $0.99 | $4,950.00 | | |
| 9/19/2014 | Lewis C Pell | Director | Buy | 3,900 | $1.00 | $3,900.00 | | |
| 9/17/2014 | Lewis C Pell | Director | Buy | 5,000 | $1.02 | $5,100.00 | | |
| 9/16/2014 | Lewis C Pell | Director | Buy | 5,000 | $1.07 | $5,350.00 | | |
| 9/12/2014 | Lewis C Pell | Director | Buy | 23,300 | $1.04 | $24,232.00 | | |
| 9/8/2014 | Lewis C Pell | Director | Buy | 30,000 | $1.04 | $31,200.00 | | |
| 9/3/2014 | Lewis C Pell | Director | Buy | 30,000 | $0.98 | $29,400.00 | | |
| 8/27/2014 | Lewis C Pell | Director | Buy | 10,000 | $0.92 | $9,200.00 | | |
| 8/26/2014 | Lewis C Pell | Director | Buy | 30,000 | $0.93 | $27,900.00 | | |
| 8/19/2014 | Lewis C Pell | Director | Buy | 22,900 | $0.98 | $22,442.00 | | |
| 8/13/2014 | Lewis C Pell | Director | Buy | 43,420 | $0.91 | $39,512.20 | | |
| 8/8/2014 | Lewis C Pell | Director | Buy | 27,500 | $0.95 | $26,125.00 | | |
| 6/6/2014 | Lewis C Pell | Director | Buy | 10,000 | $1.13 | $11,300.00 | | |
| 5/21/2014 | Lewis C Pell | Director | Buy | 5,000 | $1.09 | $5,450.00 | | |
| 5/16/2014 | Lewis C Pell | Director | Buy | 14,197 | $1.02 | $14,480.94 | | |
| 11/18/2013 | Lewis C Pell | Director | Buy | 6,296 | $0.91 | $5,729.36 | | |
| 11/15/2013 | Lewis C Pell | Director | Buy | 20,000 | $0.90 | $18,000.00 | | |
| 9/18/2013 | Lewis C Pell | Director | Buy | 16,000 | $0.91 | $14,560.00 | | |
| 9/13/2013 | Lewis C Pell | Director | Buy | 5,000 | $0.92 | $4,600.00 | | |
| 9/10/2013 | Lewis C Pell | Director | Buy | 5,000 | $0.92 | $4,600.00 | | |
| 9/9/2013 | Lewis C Pell | Director | Buy | 4,564 | $0.95 | $4,335.80 | | |
| 9/6/2013 | Lewis C Pell | Director | Buy | 5,000 | $0.97 | $4,850.00 | | |
| 9/3/2013 | Lewis C Pell | Director | Buy | 11,432 | $0.97 | $11,089.04 | | |
| 8/29/2013 | Lewis C Pell | Director | Buy | 1,100 | $0.98 | $1,078.00 | | |
| 8/27/2013 | Lewis C Pell | Director | Buy | 11,596 | $0.97 | $11,248.12 | | |
| 8/26/2013 | Lewis C Pell | Director | Buy | 14,965 | $0.97 | $14,516.05 | | |
| 8/19/2013 | Lewis C Pell | Director | Buy | 25,025 | $0.94 | $23,523.50 | | |
| 8/15/2013 | Lewis C Pell | Director | Buy | 15,000 | $0.92 | $13,800.00 | | |
| 6/28/2013 | Lewis C Pell | Director | Buy | 28,400 | $1.00 | $28,400.00 | | |
| 6/27/2013 | Lewis C Pell | Director | Buy | 45,048 | $0.99 | $44,597.52 | | |
| 3/15/2013 | Lewis C Pell | Director | Buy | 30,000 | $1.14 | $34,200.00 | | |
| 3/12/2013 | Lewis C Pell | Director | Buy | 45,000 | $1.10 | $49,500.00 | | |
| 3/7/2013 | Lewis C Pell | Director | Buy | 60,000 | $1.09 | $65,400.00 | | |
| 3/4/2013 | Lewis C Pell | Director | Buy | 20,000 | $1.06 | $21,200.00 | | |
| 2/26/2013 | Lewis C Pell | Director | Buy | 66,266 | $1.01 | $66,928.66 | | |
| 2/21/2013 | Lewis C Pell | Director | Buy | 25,000 | $0.99 | $24,750.00 | | |
| 2/19/2013 | Lewis C Pell | Director | Buy | 5,000 | $0.99 | $4,950.00 | | |
| 2/7/2013 | Lewis C Pell | Director | Buy | 9,000 | $0.99 | $8,910.00 | | |
| 2/5/2013 | Lewis C Pell | Director | Buy | 25,000 | $1.01 | $25,250.00 | | |
| 2/1/2013 | Lewis C Pell | Director | Buy | 10,000 | $1.09 | $10,900.00 | | |
| 12/27/2012 | Lewis C Pell | Director | Buy | 10,000 | $1.07 | $10,700.00 | | |
| 12/17/2012 | Lewis C Pell | Director | Buy | 21,600 | $1.10 | $23,760.00 | | |
| 12/13/2012 | Lewis C Pell | Director | Buy | 18,961 | $1.10 | $20,857.10 | | |
| 12/10/2012 | Lewis C Pell | Director | Buy | 6,656 | $1.10 | $7,321.60 | | |
| 12/3/2012 | Lewis C Pell | Director | Buy | 8,360 | $1.10 | $9,196.00 | | |
| 11/30/2012 | Lewis C Pell | Director | Buy | 45,748 | $1.10 | $50,322.80 | | |
| 11/27/2012 | Lewis C Pell | Director | Buy | 3,593 | $1.10 | $3,952.30 | | |
| 11/23/2012 | Lewis C Pell | Director | Buy | 39,357 | $1.09 | $42,899.13 | | |
| 11/19/2012 | Lewis C Pell | Director | Buy | 57,050 | $1.08 | $61,614.00 | | |
| 11/14/2012 | Lewis C Pell | Director | Buy | 100,000 | $1.15 | $115,000.00 | | |
| 11/12/2012 | Lewis C Pell | Director | Buy | 24,852 | $1.17 | $29,076.84 | | |
| 9/6/2012 | Lewis C Pell | Director | Buy | 10,000 | $1.37 | $13,700.00 | | |
(Data available from 1/1/2013 forward)
Vision Sciences (NASDAQ CGNT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Vision Sciences Inc. (CGNT) Given $4.23 Consensus Price Target by Analysts
www.americanbankingnews.com - April 20 at 9:22 PM |
| Financial Analysis: Zynex (ZYXI) versus Vision Sciences (CGNT)
www.americanbankingnews.com - April 13 at 5:09 AM |
| Financial Survey: NxStage (NXTM) and Vision Sciences (CGNT)
www.americanbankingnews.com - April 12 at 9:20 AM |
| Vision Sciences (CGNT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:42 PM |
 | The Law Offices of Vincent Wong Reminds Investors of an Investigation into Cogentix Medical, Inc. in Connection with the Sale of the Company to LABORIE Medical Technologies
finance.yahoo.com - April 9 at 4:38 PM |
| Vision Sciences Inc. (CGNT) Given $4.23 Average Target Price by Analysts
www.americanbankingnews.com - April 3 at 9:18 AM |
| Vision Sciences (CGNT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 2 at 8:40 PM |
| Roth Capital Initiates Coverage on Vision Sciences (CGNT)
www.americanbankingnews.com - April 1 at 9:06 AM |
| Is It Time To Buy Cogentix Medical Inc (NASDAQ:CGNT)?
finance.yahoo.com - March 30 at 9:16 AM |
| Cogentix Medical (CGNT) Stock Rating Lowered by Roth Capital
www.americanbankingnews.com - March 23 at 6:36 PM |
| SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cogentix Medical, Inc.- CGNT
finance.yahoo.com - March 23 at 9:10 AM |
| Cogentix Medical (CGNT) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - March 23 at 1:10 AM |
| The Law Offices of Vincent Wong Notifies Investors of an Investigation into Cogentix Medical, Inc. in Connection with the Sale of the Company to LABORIE Medical Technologies
finance.yahoo.com - March 21 at 10:15 AM |
| COGENTIX MEDICAL, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale to LABORIE Medical Technologies, Inc.
finance.yahoo.com - March 19 at 4:35 PM |
| SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Cogentix Medical, Inc. and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - March 16 at 5:40 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Cogentix Medical, Inc. to LABORIE Medical Technologies is Fair to Shareholders – CGNT
finance.yahoo.com - March 16 at 5:40 PM |
| WeissLaw LLP Investigates Cogentix Medical, Inc. Acquisition
finance.yahoo.com - March 15 at 5:11 PM |
| COGENTIX MEDICAL, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - March 14 at 6:02 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Cogentix Medical, Inc. to LABORIE Medical Technologies is Fair to Shareholders
finance.yahoo.com - March 14 at 6:02 PM |
| Cogentix Medical (CGNT) Downgraded by Aegis to Hold
www.americanbankingnews.com - March 13 at 3:10 PM |
 | Cogentix Medical (CGNT) to be Acquired by Laborie Medical Technologies for $3.85 Per Share in Cash
www.streetinsider.com - March 13 at 9:27 AM |
 | Medical-device maker Cogentix to be sold in deal worth $239M
www.bizjournals.com - March 13 at 9:27 AM |
| Here's Why Cogentix Medical Inc. Stock Is Surging Today
finance.yahoo.com - March 13 at 9:27 AM |
| Cogentix Medical Inc to Host Earnings Call
finance.yahoo.com - March 12 at 5:44 PM |
| Cogentix Medical Enters Definitive Merger Agreement to be Acquired by Laborie Medical Technologies for a Purchase Price of $3.85 Per Share in Cash
finance.yahoo.com - March 12 at 11:27 AM |
| Here's Why Cogentix Medical Inc. Stock Is Surging Today
finance.yahoo.com - March 12 at 11:27 AM |
| Broadfin Capital LLC Sells 333,540 Shares of Cogentix Medical Inc (CGNT)
www.americanbankingnews.com - March 3 at 4:55 AM |
| Cogentix Medical to Report Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018
finance.yahoo.com - March 1 at 8:58 AM |
| Cogentix Medical (CGNT) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:24 AM |
| Comparing Cogentix Medical (CGNT) & Mazor Robotics (MZOR)
www.americanbankingnews.com - February 13 at 10:54 AM |
| Cogentix Medical (CGNT) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 12 at 7:18 PM |
| Cogentix Medical Announces 17% Preliminary Fourth Quarter 2017 Year-Over-Year Revenue Growth
finance.yahoo.com - February 6 at 9:18 AM |
| Cogentix Medical (CGNT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 1 at 7:14 PM |
| Zacks: Cogentix Medical, Inc. (CGNT) Given $4.58 Consensus Target Price by Analysts
www.americanbankingnews.com - January 17 at 11:40 AM |
 | Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?
www.zacks.com - December 29 at 9:58 AM |
| ETFs with exposure to Cogentix Medical, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:02 PM |
| Head to Head Analysis: Cogentix Medical (CGNT) and Accuray (ARAY)
www.americanbankingnews.com - December 28 at 3:44 PM |
| Cogentix Medical, Inc. :CGNT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 2:24 PM |
| Cogentix Medical (CGNT) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - December 20 at 5:56 PM |
| ETFs with exposure to Cogentix Medical, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 5:41 PM |
| Reviewing Cogentix Medical (CGNT) & Mindray Medical International (MR)
www.americanbankingnews.com - December 7 at 5:30 AM |
| Cogentix Medical Announces Palmetto GBA Extends Medicare Coverage on Urgent® PC
finance.yahoo.com - December 6 at 9:26 AM |
| Cogentix Medical (CGNT) in Focus: Stock Moves 6.6% Higher
www.zacks.com - December 4 at 9:13 AM |
| Aegis Initiates Coverage on Cogentix Medical (CGNT)
www.americanbankingnews.com - December 1 at 8:56 AM |
| Brokerages Anticipate Cogentix Medical, Inc. (CGNT) to Announce $0.00 EPS
www.americanbankingnews.com - November 28 at 5:36 AM |
| Zacks: Cogentix Medical, Inc. (CGNT) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - November 21 at 5:23 PM |
| Cogentix Medical (CGNT) vs. Edwards Lifesciences Corporation (EW) Head to Head Survey
www.americanbankingnews.com - November 19 at 11:36 AM |
| Cogentix Medical, Inc. (CGNT) Upgraded to "C" at TheStreet
www.americanbankingnews.com - November 11 at 1:38 PM |
| Edited Transcript of CGNT earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 8:51 PM |
| Why Cogentix Medical Inc (CGNT) Could Be A Buy
finance.yahoo.com - November 7 at 8:07 PM |
Vision Sciences (NASDAQ:CGNT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vision Sciences (NASDAQ:CGNT) Income Statement, Balance Sheet and Cash Flow Statement
Vision Sciences (NASDAQ CGNT) Stock Chart for Sunday, April, 22, 2018
Loading chart…
